Evolus (EOLS) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evolus (EOLS) has outperformed Prothena (PRTA) over the past year, losing 4.8% versus a loss of 21.6%. Over five years, EOLS leads with a +14.4% price change compared with -83.3% for PRTA. Evolus is the larger company by market cap ($431.5 million vs $422.1 million), about 1.0 times the size.
Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -2520.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | PRTA |
|---|---|---|
| Share price | $6.52 | $8.22 |
| Market cap | $431.55M | $422.10M |
| 1-day change | -6.86% | -2.14% |
| YTD return | -1.95% | -13.93% |
| 1-year return | -4.82% | -21.56% |
| 5-year return | +14.39% | -83.28% |
| Forward P/E | 22.68 | — |
| EPS (TTM) | $-0.48 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $297.18M | $9.68M |
| Revenue growth (YoY) | +11.61% | -92.83% |
| Net income (latest FY) | $-51.64M | $-244.09M |
| Gross margin | 66.33% | — |
| Operating margin | -10.99% | -2216.44% |
| Net margin | -17.38% | -2520.57% |
| 52-week high | $9.31 | $11.80 |
| 52-week low | $3.86 | $7.70 |
| Distance from 52-week high | -29.97% | -30.34% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +136.20% | +160.34% |
| Average volume | 925.77K | 487.91K |
| Shares outstanding | 66.19M | 51.35M |
| Employees | 365 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed PRTA by 16.7 percentage points over the past year.
- Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -2520.6 cents for Prothena.
- Evolus grew revenue faster in its latest fiscal year (+11.61% vs -92.83%).
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
EOLS vs PRTA FAQ
Which is bigger, Evolus or Prothena?
Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $422.10M for Prothena (PRTA).
Which stock has performed better over the past year, EOLS or PRTA?
EOLS returned -4.82% over the past 12 months, compared with -21.56% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.